These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Alglucosidase alfa therapy for Pompe disease in pregnancy - Case report. Kłos J; Kwaśniak-Butowska M; Sławek J J Neurol Sci; 2017 Apr; 375():167-169. PubMed ID: 28320122 [No Abstract] [Full Text] [Related]
7. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Kishnani PS; Beckemeyer AA Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093 [TBL] [Abstract][Full Text] [Related]
8. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. Han SO; Li S; Bird A; Koeberl D Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913 [TBL] [Abstract][Full Text] [Related]
9. Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice. Yiu WH; Pan CJ; Mead PA; Starost MF; Mansfield BC; Chou JY J Hepatol; 2009 Nov; 51(5):909-17. PubMed ID: 19376605 [TBL] [Abstract][Full Text] [Related]
10. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143 [TBL] [Abstract][Full Text] [Related]
11. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673 [TBL] [Abstract][Full Text] [Related]
12. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263 [TBL] [Abstract][Full Text] [Related]
13. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924 [TBL] [Abstract][Full Text] [Related]
14. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703 [TBL] [Abstract][Full Text] [Related]
15. Pompe disease: early diagnosis and early treatment make a difference. Chien YH; Hwu WL; Lee NC Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029 [TBL] [Abstract][Full Text] [Related]
16. Fractures in children with Pompe disease: a potential long-term complication. Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521 [TBL] [Abstract][Full Text] [Related]
17. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Lacaná E; Yao LP; Pariser AR; Rosenberg AS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234 [TBL] [Abstract][Full Text] [Related]